LumiraDx shares are trading higher after the company received UK approval for its COVID Ultra and COVID & RSV Tests.
Portfolio Pulse from Benzinga Newsdesk
LumiraDx received UK approval for its COVID Ultra and COVID & RSV Tests, leading to a surge in its share prices.
June 21, 2023 | 8:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LumiraDx shares are trading higher after the company received UK approval for its COVID Ultra and COVID & RSV Tests.
The UK approval for LumiraDx's COVID Ultra and COVID & RSV Tests is a significant milestone for the company, as it expands its market reach and potential revenue. This positive news directly impacts the company's stock price, leading to an increase in share value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100